title: Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
abstract: Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n = 24; P < 0.01), compared with vincristine (n = 9) or doxorubicin (n = 5). Therefore, the therapeutic outcome of traditional CHOP-based chemotherapy might be improved by replacing cyclophosphamide with other cytotoxic drugs.
authors.affiliation: National Taiwan University Veterinary Hospital, College of Bioresources and Agriculture, National Taiwan University, Taipei, 10672, Taiwan; Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, 10617, Taiwan.
authors.forename: Shang-Lin
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Graduate Institute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei, 10617, Taiwan; Animal Cancer Center, College of Bioresources and Agriculture, National Taiwan University, Taipei, 10617, Taiwan.
authors.forename: Jih-Jong
authors.initials: JJ
authors.lastname: Lee
authors.affiliation: Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, 10617, Taiwan; Animal Cancer Center, College of Bioresources and Agriculture, National Taiwan University, Taipei, 10617, Taiwan. Electronic address: atliao@ntu.edu.tw.
authors.forename: Albert Taiching
authors.initials: AT
authors.lastname: Liao
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Canine; Chemotherapy; Cyclophosphamide; Lymphoma; Relapse